Efficacy of IOP reduction and safety of Tapcom combination ophthalmic solution switched from Tapros 0.0015% and Timoptol XE 0.5% / Rysmon TG 0.5% ophthalmic solution.
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2016
At a glance
- Drugs Tafluprost/timolol (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; Therapeutic Use
- 26 Dec 2016 Status changed from recruiting to completed.
- 06 Jan 2015 New trial record